London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Company will be raising cash soon to complete FDA trials and pilots
How much and at what market price is the question
This has been falling for a long time , just look at the chart
Market is pricing in a fund raising , it is public knowledge
Believe that they also have a patent for gum disease based on same laser technology. Looks like they need a big partner to really make this take off as again, this dental treatment has a massive market worldwide.
Hope the big cash starts coming in soon as this could be megga. Only put in £2K as there are still some risks along the way but the potential return could be off the scale....He who dares Rodney....
2.5 million saving per hospital at current rates by reducing the infections based on the initial data!
Wow, nice!
A great listen that was
This company is going to be a blockbuster if it’s not bought out.
https://www.proactiveinvestors.com/companies/news/1031918/ondine-biomedical-s-steriwave-platform-seeing-strong-adoption-as-company-receives-key-data-1031918.html
Expect 25p+ by year-end
is my wild estimate
dyor imho
once all the dip **** traders have moved on then sp price will have a more realistic value .
Alberta Health Services has expanded its use of Steriwave nasal #photodisinfection to reduce the incidence of surgical site infections (SSIs) in orthopedic surgery following a successful pilot at the Mazankowski Alberta Heart Institute #infectioncontrol
This baby is going to brilliant i m h o
I have no doubt this is heading to 15-18p by Christmas.
The news will keep coming and be relentless.
Do not be out of this company it’s only going one way from here!!!
This could be one of the biggest medical cost saving devices in history.
It’s an absolute no brainer for every hospital in the world to take this device on board.
The initial cost is covered easily by the cost savings.
The company makes money from the device purchase, blue solution pumped Into the nasal cavity, and also from the changeable light carrying probes that go into the nose.
This makes the company an ongoing cash cow and very very profitable.
Investors are slowly waking up to the absolutely massive potential here. BUY!!
Please see the information below:-
“Canadian hospitals implemented our photodisinfection technology for orthopedic, spinal, and several other surgical specialties with compelling results in the first year.*
42% surgical site infection reduction.
CAD $1.9M costs avoided + 552 bed-days saved.
3,068 surgical patients decolonized during initial year.
94% compliance with decolonization.
3.7x reduction in surgical site infection (SSI) risk (P=0.00026).
Since 2011, Steriwave has become a key component of the hospital’s surgical infection control efforts that, together with NSQIP and additional surgical bundles added in the intervening years, have led to the hospital reducing its overall SSI rate to less than 0.5%.”
It’s a total no brainer buying into this company.
It’s a totally solid proven product that’s going to revolutionise surgery and problems with bacteria, fungus etcetc in the patient and I guess doctors and nurses nasal passages.
Definately worth a punt on this one after trails updates. Can see this Co being bought out for their product as the market is massive.
I think the product would be great for travellers. How many times do you fly and are then ill for a few days after.
Professional sports teams/athletes too.
It is a no brainer. Trials have been good and will be a matter of time until it is used more
The uptake of Steriwave will accelerate from here.
This could be in every hospital in the world within a short space of time.
Anti biotic resistance is a real curse and problem.
This addresses that problem to a large extent.
Anyone have any idea how much OBI sell their product for? I can't find any info anywhere
Expect 20p very soon
inho - dyor
(Alliance News) - Ondine Biomedical Inc on Tuesday said Alberta Health Services has expanded the use of its Steriwave naval photodisinfection technology following a successful pilot at the Mazankowski Alberta Heart Institute.
Shares in the Vancouver-based life sciences company jumped 23% to 12.90 pence each in London on Tuesday afternoon.
Ondine said after a successful pilot study at the Manzankowski Alberta Heart Institute, the device will now be used at the Royal Alexandra Hospital in Edmonton ahead of 3,000 planned orthopaedic surgeries in the next twelve months.
Last week, Ondine reported that Steriwave helped reduce spine surgery infection rates by 67% at Vancouver General Hospital, following an eight-year study conducted by VGH and University of British Columbia hospital.
Steriwave employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues.
Chief Executive Officer Carolyn Cross said: "We are very pleased to be collaborating with Alberta Health Services to reduce the incidence of [surgical site infections] in Alberta without generating antibiotic resistance. The successful initial implementation of Steriwave into the pre-surgical treatment protocols at the Mazankowski Alberta Heart Institute has driven rapid adoption of Steriwave for orthopedic surgeries at the Royal Alexandra Hospital."
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Up 23% and this is only the beginning
3000 surgeries WOW!!
Ondine said after a successful pilot study at the Manzankowski Alberta Heart Institute, the device will now be used at the Royal Alexandra Hospital in Edmonton ahead of 3,000 planned orthopaedic surgeries in the next twelve months.
Last week, Ondine reported that Steriwave helped reduce spine surgery infection rates by 67% at Vancouver General Hospital, following an eight-year study conducted by VGH and University of British Columbia hospital.
(Alliance News) - Ondine Biomedical Inc on Tuesday said Alberta Health Services has expanded the use of its Steriwave naval photodisinfection technology following a successful pilot at the Mazankowski Alberta Heart Institute.
Shares in the Vancouver-based life sciences company jumped 23% to 12.90 pence each in London on Tuesday afternoon.
Ondine said after a successful pilot study at the Manzankowski Alberta Heart Institute, the device will now be used at the Royal Alexandra Hospital in Edmonton ahead of 3,000 planned orthopaedic surgeries in the next twelve months.
Last week, Ondine reported that Steriwave helped reduce spine surgery infection rates by 67% at Vancouver General Hospital, following an eight-year study conducted by VGH and University of British Columbia hospital.
Steriwave employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues.
Chief Executive Officer Carolyn Cross said: "We are very pleased to be collaborating with Alberta Health Services to reduce the incidence of [surgical site infections] in Alberta without generating antibiotic resistance. The successful initial implementation of Steriwave into the pre-surgical treatment protocols at the Mazankowski Alberta Heart Institute has driven rapid adoption of Steriwave for orthopedic surgeries at the Royal Alexandra Hospital."
Ondine said after a successful pilot study at the Manzankowski Alberta Heart Institute, the device will now be used at the Royal Alexandra Hospital in Edmonton ahead of 3,000 planned orthopaedic surgeries in the next twelve months.
Last week, Ondine reported that Steriwave helped reduce spine surgery infection rates by 67% at Vancouver General Hospital, following an eight-year study conducted by VGH and University of British Columbia hospital.
What a roll out. And this is just the beginning.
Multi bag alert!!
Mid Yorkshire Teaching NHS Trust has this week started the first UK pilot evaluation of nasal photodisinfection for the prevention of surgical site infections at Pontefract Hospital. The six-month pilot will see 500 elective hip and knee surgery patients nasally decolonized using Ondine Biomedical’s Steriwave® nasal photodisinfection prior to their surgery.
Steriwave is already in use at a number of hospitals across Canada, including Vancouver General Hospital and The Ottawa Hospital, and has demonstrated significant improvement in post-surgical outcomes including lower rates of infection, reduced patient length of stay, fewer readmissions, and lower rates of antibiotic prescribing.
Dr Stuart Bond, Consultant Antimicrobial Pharmacist & Director of Innovation at Mid Yorkshire Teaching NHS Trust commented: “We are very pleased to be the first NHS Trust in the UK to pilot this exciting, non-antibiotic method of preventing infections after surgery. Although infections after hip and knee surgeries are rare, we know that they lengthen patients’ stay in hospital, complicate the recovery process, and cause significant pain and suffering. We look forward to sharing the results of the Steriwave pilot in due course.”
Nasal decolonization is recommended by NICE to eliminate pathogens in a patient’s nasal cavities, like MRSA, which are major causes of SSIs. A patient with a surgical site infection will, on average, spend 7 to 11 days more in hospital, significantly increasing costs and lengthening patients’ recovery. Nasal mupirocin, an antibiotic, is usually used for nasal decolonization, however, there are serious concerns about its antimicrobial resistance rates which have been reported as high as 81%.
Nasal photodisinfection is a non-antibiotic method for nasal decolonization that uses a proprietary light-activated agent to destroy pathogens. First, the agent is applied to each nostril using a nasal swab, then the area is illuminated with a specific wavelength of light. The light activates the photodynamic agent, causing an oxidative burst that destroys pathogens. In this single, 5-minute treatment, Steriwave eliminates infection-causing bacteria, viruses and fungi in the nose.